For Immediate Release: February 12, 2019
513-579-9911 x 12627
Medpace Expands In-House Medical Expertise with the Addition of 2 New Physicians
CINCINNATI, OH — (February 12, 2019) – Medpace (MEDP) a scientifically-driven, global, full-service clinical contract research organization (CRO) known for its strong therapeutic and regulatory expertise, announced the addition of two physicians to its medical leadership team. Medpace’s unique, scientifically-driven approach to clinical research embeds medical expertise throughout trial design and execution, providing a high-science approach to clinical development. With the addition of these highly-qualified physicians, Medpace can offer Sponsors even deeper expertise across a broad spectrum of diseases and technologies.
Nancy Campbell, MD
Dr. Nancy Campbell is board certified in Family Medicine with over 25 years of experience in clinical practice, academia and industry. She was in practice and a Clinical Assistant Professor of Family Medicine for almost 10 years, before entering into a dedicated clinical research practice for 14+ years. As Medical Director of 2 clinical research centers, she participated as the Principal Investigator on more than 140 multi-specialty clinical trials in Phase I-IV in both adults and pediatrics in the therapeutic areas of allergy/immunology, CNS, metabolic, respiratory, urology, vaccines, cardiovascular, and women’s health. Immediately prior to joining Medpace, she was an Executive Medical Director at a global CRO for 5 years where she has experience as a medical monitor in rare disease, CNS, psychiatry, metabolic, GI, and respiratory in both pediatrics and adults in Phase I-IV trials.
Dr. Campbell received her medical degree from the Baylor College of Medicine in Houston Texas. After graduation, she stayed in the area and completed her residency in Family Medicine at the University of Texas Health Science Center. Dr. Campbell also spent 10+ years as a Registered Nurse in post-op cardiovascular and medical/surgical prior to her career as a physician.
Ajay Srivastava, MD, FASN
Dr. Ajay Srivastava is a board-certified nephrologist with an extensive background in both clinical and academic medicine, who has lectured at the local, regional, and national levels. Specializing in adult nephrology, he brings over 12 years of experience in both the common and rare conditions of the kidney, renal replacement therapies, ICU nephrology including IV fluid resuscitation and management, and comorbid conditions such as cardiorenal syndrome and hypertension. As an interventional nephrologist, he provides education, assistance, and evaluation regarding matters of dialysis vascular access including the performance of interventional procedures to preserve, optimize, and salvage these hemodialysis accesses. He holds an academic teaching appointment at the University of Cincinnati College of Medicine and serves as the Director of the Nephrology Fellowship Program where he is responsible for the education and training of future nephrologists. Dr. Srivastava has also held several other leadership positions including the Medical Directorship of dialysis facilities, Division Chief of Nephrology, and Interim Chair of Medicine, and has served on a number of departmental, hospital, and university committees. With the addition of Dr. Srivastava, Medpace further strengthens its capabilities in clinical development across a full range of renal indications for both drug and medical devices.
Dr. Srivastava graduated with honors from the University of Rochester with a Bachelor of Arts in Psychology and subsequently earned his medical degree from the University of Texas Medical Branch. His postgraduate training was completed at the University of Rochester Medical Center and includes his residency in internal medicine and his fellowship in Nephrology. He holds board certifications in both Nephrology and Internal Medicine.
Medpace is a scientifically-driven, global, full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. Medpace’s mission is to accelerate the global development of safe and effective medical therapeutics through its high-science and disciplined operating approach that leverages local regulatory and deep therapeutic expertise across all major areas including oncology, cardiology, metabolic disease, endocrinology, central nervous system and anti-viral and anti-infective. Headquartered in Cincinnati, Ohio, Medpace employs approximately 2,800 people across 36 countries.